4 news items
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
DAWN
18 Jun 24
-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our
Day One Announces Sale of Priority Review Voucher for $108 Million
DAWN
30 May 24
and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
DAWN
6 May 24
-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our
Day One's OJEMDAâ„¢ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
DAWN
23 Apr 24
statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove
- Prev
- 1
- Next